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Background: Cancer patients are at increased risk of venous thrombotic events (VTE).
Tissue factor (TF) is the primary initiator of blood coagulation and preclinical data
suggest that its expression is also controlled by KRAS. Higher levels of TF seem to be
associated with mutations of KRAS; the latter therefore might be a plausible link to
hypercoagulability and increased VTE risk for metastatic colorectal cancer (mCRC)
patients (pts).
Patients and methods: A retrospective case-control study was conducted. Cases had
VTE (deep vein thrombosis (DVT), pulmonary embolism (PE), and/or migratory
superficial thrombophlebitis) occurring after diagnosis of metastatic disease. Controls
were pts with mCRC without VTE, matched for age, sex, year of diagnosis of metastatic
disease, and presence of a central venous access device. Cases and controls were identified
from the electronic health records of the Department of Oncology, Udine, and of the
Department of Oncology, Pisa. Formalin-fixed, paraffin-embedded samples were reviewed
and tested by pyrosequencing for KRAS status (codons 12, 13, 61
and 146). Estimating that about 40% of mCRC harbor a KRAS mutation and with a cases/
controls ratio of 1:2, the sample size needed to determine a significant odds ratio (OR) of
2.5 was approximately 77 cases and 154 controls, with α = 0.05 and a power of 80%.
Results: Between January 2008 and December 2014 a total of 68 cases with VTE and
177 controls without VTE were included. Thirty-four of the cases had DVT, 34 had PE.
Of note, 6 patients had both thrombotic events. When VTE occurred, 37% of pts were
receiving a bevacizumab-containing regimen. Among the controls, 38% received
bevacizumab. Fifty-three (78%) of the cases and 137 (77%) of the controls had a central
venous access device. The OR for thrombosis in KRAS mutated (codon 12, 13, 61 and
146) mCRC pts was 1.34 (95%CI 0.77-2.36, p = 0.303).
Conclusions: Despite the trend towards an increased risk of VTE for pts with
KRAS-mutant mCRC, our results were not statistically significant and did not confirm
the findings of a similar retrospective study conducted in pts with mCRC [Ades S, et al.
J Thromb Haemost 2015]. Whether tumor genetic profile may contribute to the
thrombotic risk assessment of CRC cancer pts remains uncertain.
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